5-HT3 Antagonist Ondansetron Increases apoE Secretion by Modulating the LXR-ABCA1 Pathway

APOE ε4/ε4 diminishes neurotrophic function of human iPSC-derived astrocytes

(2017) Jing Zhao et al.   HUMAN MOLECULAR GENETICS

Geranylgeranyl pyrophosphate performs as an endogenous regulator of adipocyte function via suppressing the LXR pathway

(2016) Yu-Sheng Yeh et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Plasma levels of apolipoprotein E and risk of dementia in the general population

(2015) Katrine L. Rasmussen et al.   ANNALS OF NEUROLOGY

Ondansetron attenuates co-morbid depression and anxiety associated with obesity by inhibiting the biochemical alterations and improving serotonergic neurotransmission

(2015) Yeshwant Kurhe et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer’s disease

(2014) Mitsuru Shinohara et al.   BRAIN

Ondansetron, a 5HT3 receptor antagonist reverses depression and anxiety-like behavior in streptozotocin-induced diabetic mice: Possible implication of serotonergic system

(2014) Deepali Gupta et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Ondansetron: a review of pharmacokinetics and clinical experience in postoperative nausea and vomiting

(2014) M Christofaki et al.   Expert Opinion on Drug Metabolism & Toxicology

Retinoic Acid Isomers Facilitate Apolipoprotein E Production and Lipidation in Astrocytes through the Retinoid X Receptor/Retinoic Acid Receptor Pathway

(2014) Jing Zhao et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Amyloid-β Pathology andAPOEGenotype Modulate Retinoid X Receptor Agonist Activityin Vivo

(2014) Leon M. Tai et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Liver X receptors in lipid metabolism: opportunities for drug discovery

(2014) Cynthia Hong et al.   NATURE REVIEWS DRUG DISCOVERY

ApoE and Aβ in Alzheimer’s Disease: Accidental Encounters or Partners?

(2014) Takahisa Kanekiyo et al.   NEURON

Meta-Analysis of Peripheral Blood Apolipoprotein E Levels in Alzheimer’s Disease

(2014) Chong Wang et al.   PLoS One

Brain regional correlation of amyloid-β with synapses and apolipoprotein E in non-demented individuals: potential mechanisms underlying regional vulnerability to amyloid-β accumulation

(2013) Mitsuru Shinohara et al.   ACTA NEUROPATHOLOGICA

Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy

(2013) Chia-Chen Liu et al.   Nature Reviews Neurology

PAPP-A negatively regulates ABCA1, ABCG1 and SR-B1 expression by inhibiting LXRα through the IGF-I-mediated signaling pathway

(2012) Shi-Lin Tang et al.   ATHEROSCLEROSIS

Cyclosporine A and PSC833 inhibit ABCA1 function via direct binding

(2012) Kohjiro Nagao et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease

(2012) Carlos Cruchaga et al.   HUMAN MOLECULAR GENETICS

ApoE-Directed Therapeutics Rapidly Clear  -Amyloid and Reverse Deficits in AD Mouse Models

(2012) P. E. Cramer et al.   SCIENCE

The anti-aggregation effects of ondansetron on platelets involve IP3 signaling and MAP kinase pathway, but not 5-HT3-dependent pathway

(2012) Fu-Chao Liu et al.   THROMBOSIS RESEARCH

Systemic treatment with liver X receptor agonists raises apolipoprotein E, cholesterol, and amyloid-β peptides in the cerebral spinal fluid of rats

(2010) Sokreine Suon et al.   Molecular Neurodegeneration

Serotonergic modulation of extrapyramidal motor disorders in mice and rats: Role of striatal 5-HT3 and 5-HT6 receptors

(2010) Yukihiro Ohno et al.   NEUROPHARMACOLOGY

Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy

(2009) Guojun Bu   NATURE REVIEWS NEUROSCIENCE

Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels

(2008) D. R. Riddell et al.   JOURNAL OF NEUROSCIENCE

ApoE Promotes the Proteolytic Degradation of Aβ

(2008) Qingguang Jiang et al.   NEURON